The expression of PD‐L1 in NSCLC, renal cell carcinoma, melanoma, bladder cancer, and other types of solid tumors was related to the better efficacy of PD‐L1 inhibitors.32 The gene discussed is CD274; the disease is renal cell carcinoma.